John McB. Hodgson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
John McB. Hodgson has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Gregg W. Stone
Columbia University Medical Center, New York Presbyterian Hospital and the Cardiovascular Research Foundation, New York, New York
3 shared publicationsA. Michael Lincoff
1 shared publicationBonnie H. Weiner
1 shared publicationBrian G. Firth
1 shared publication- Dan Greenberg
Department of Health Policy and Management, School of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be’er-Sheva 84105, Israel
1 shared publication - David G. Rizik
Department of Cardiology, Banner University Medical Center, Scottsdale, Arizona, USA
1 shared publication
Latest Publications
- 20 June 2025
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 81, 78-79
Editorial: Intravascular imaging during coronary intervention. Why is there still resistance to full adoption?
- 20 June 2025
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 81, 78-79
Editorial: Intravascular imaging during coronary intervention. Why is there still resistance to full adoption?
- 1 May 2019
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 12 (5) , 873-874
Let’s Join Them!
- 1 May 2019
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 12 (5) , 873-874
Let’s Join Them!
- 1 April 2018
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 11 (7) , 662-664
Why Do We Still Tolerate “Suboptimal Deployment”?
- 1 April 2018
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 11 (7) , 662-664
Why Do We Still Tolerate “Suboptimal Deployment”?
- 1 January 2018
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 11 (1) , 124-126
How Quickly We Forget
- 1 January 2018
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 11 (1) , 124-126
How Quickly We Forget
- 5 July 2016
- Published by Springer Nature in Current Cardiovascular Imaging Reports
- Vol. 9 (8) , 1-9
Enhanced IVUS: Advances Allowing Higher Resolution and Integrated Devices
- 5 July 2016
- Published by Springer Nature in Current Cardiovascular Imaging Reports
- Vol. 9 (8) , 1-9
Enhanced IVUS: Advances Allowing Higher Resolution and Integrated Devices
- 16 June 2015
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 28 (4) , 326-338
Interventional Management of Unprotected Left Main Coronary Artery Disease: Patient Selection and Technique Optimization
For many years, coronary artery bypass graft surgery has been the gold standard for revascularization of patients with left main disease; however, increasing evidence suggests that percutaneous coronary intervention with drug‐eluting stents may be an acceptable alternative or even preferred in select cases. This review will present clinical evidence examining the outcomes of drug‐eluting stents compared to coronary artery bypass graft surgery for unprotected left main coronary artery disease and discuss the anatomic factors, patient variables, and clinical strategies that may dictate choice of revascularization modality for patients with left main disease. If percutaneous coronary intervention is selected to treat unprotected left main disease, meticulous technique is essential to optimize outcomes, including use of procedural physiology and imaging guidance, optimal stent and adjunct pharmacology use, and expert management of the distal bifurcation. Finally, issues of equipoise and uncertainty are identified, representing areas for future investigation.
- 16 June 2015
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 28 (4) , 326-338
Interventional Management of Unprotected Left Main Coronary Artery Disease: Patient Selection and Technique Optimization
For many years, coronary artery bypass graft surgery has been the gold standard for revascularization of patients with left main disease; however, increasing evidence suggests that percutaneous coronary intervention with drug‐eluting stents may be an acceptable alternative or even preferred in select cases. This review will present clinical evidence examining the outcomes of drug‐eluting stents compared to coronary artery bypass graft surgery for unprotected left main coronary artery disease and discuss the anatomic factors, patient variables, and clinical strategies that may dictate choice of revascularization modality for patients with left main disease. If percutaneous coronary intervention is selected to treat unprotected left main disease, meticulous technique is essential to optimize outcomes, including use of procedural physiology and imaging guidance, optimal stent and adjunct pharmacology use, and expert management of the distal bifurcation. Finally, issues of equipoise and uncertainty are identified, representing areas for future investigation.
- Open Access
- 11 January 2007
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 69 (3) , 327-333
Late stent thrombosis: Considerations and practical advice for the use of drug‐eluting stents: A report from the Society for Cardiovascular Angiography and Interventions drug‐eluting stent task force
- 11 January 2007
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 69 (3) , 327-333
Open AccessLate stent thrombosis: Considerations and practical advice for the use of drug‐eluting stents: A report from the Society for Cardiovascular Angiography and Interventions drug‐eluting stent task force
- 15 April 2004
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 62 (1) , 1-17
Drug‐eluting stent task force: Final report and recommendations of the working committees on cost‐effectiveness/economics, access to care, and medicolegal issues
Coronary artery disease remains a major health problem worldwide. Since introduction of percutaneous transluminal coronary angioplasty and stents, much progress has been made. Percutaneous coronary intervention, however, has been limited by restenosis (repeat obstruction of arteries that have been previously treated. Introduction of drug‐eluting stents (DESs) in April 2003 was a major breakthrough in preventing restenosis. In March 2003, The Society for Cardiovascular Angiography and Interventions (SCAI) published a position statement on the clinical implications of DESs, recommending an evidence‐based adoption strategy. Subsequently, in May 2003, SCAI formed a multidisciplinary Drug Eluting Stent (DES) Task Force to address the significant nonclinical ramifications posed by DESs: medicolegal, financial, and access to care. The Task Force included representatives from physician societies, industry, academia, the reimbursement community, and health policy organizations. The resultant report presents analyses, options, and recommendations regarding those nonclinical issues based on the collective experience and knowledge of the Task Force members. The Task Force trusts that this report will be of value to the diverse constituencies involved with introduction of this important new technology. Catheter Cardiovasc Interv 2004;62: 1–17.
- 15 April 2004
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 62 (1) , 1-17
Drug‐eluting stent task force: Final report and recommendations of the working committees on cost‐effectiveness/economics, access to care, and medicolegal issues
Coronary artery disease remains a major health problem worldwide. Since introduction of percutaneous transluminal coronary angioplasty and stents, much progress has been made. Percutaneous coronary intervention, however, has been limited by restenosis (repeat obstruction of arteries that have been previously treated. Introduction of drug‐eluting stents (DESs) in April 2003 was a major breakthrough in preventing restenosis. In March 2003, The Society for Cardiovascular Angiography and Interventions (SCAI) published a position statement on the clinical implications of DESs, recommending an evidence‐based adoption strategy. Subsequently, in May 2003, SCAI formed a multidisciplinary Drug Eluting Stent (DES) Task Force to address the significant nonclinical ramifications posed by DESs: medicolegal, financial, and access to care. The Task Force included representatives from physician societies, industry, academia, the reimbursement community, and health policy organizations. The resultant report presents analyses, options, and recommendations regarding those nonclinical issues based on the collective experience and knowledge of the Task Force members. The Task Force trusts that this report will be of value to the diverse constituencies involved with introduction of this important new technology. Catheter Cardiovasc Interv 2004;62: 1–17.